Lung Cancer | Tumor

Real-World Patients May Have More Side Effects to Immunotherapy for Lung Cancer Compared With Clinical Trial Data

January 20th 2021, 7:00pm

Article

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Patients With Lung Cancer Subset Report Better Quality of Life, Improved Survival After Treatment with Lorbrena

January 13th 2021, 7:00pm

Article

Patients with ALK-positive non-small-cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori.

Novel Therapy-Tecentriq Combo Receives Breakthrough Designation from FDA for Non-Small Cell Lung Cancer

January 6th 2021, 8:00pm

Article

The FDA based its decision on data that demonstrated that the novel therapy in combination with Tecentriq induced a higher overall response to therapy compared to Tecentriq alone in patients with PD-L1-positive non-small cell lung cancer.

Lorbrena Granted Priority Review By FDA for Treatment of Previously Untreated Non-Small Cell Lung Cancer Subtype

January 6th 2021, 4:00pm

Article

The FDA granted a priority review to the supplemental new drug application for Lorbrena for the firstline treatment of ALK-positive metastatic non-small cell lung cancer.

Bristol-Myers Squibb Pulls Small Cell Lung Cancer Indication for Opdivo

January 4th 2021, 4:00pm

Article

The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.

Communication With the Treatment Team, Self-Advocacy Play Important Roles in Small Cell Lung Cancer

January 2nd 2021, 3:00pm

Article

In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.

Medicaid Expansion Effects Mortality for Patients with Cancer

December 23rd 2020, 4:00pm

Article

Mortality rate for patients with cancer decreases due to Medicaid expansion for patients with newly diagnosed breast, colorectal and lung cancer.

Immunotherapy Side Effects: Know What to Look For

December 22nd 2020, 7:00pm

Article

Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.

Investigational Therapy Granted Breakthrough Designation for Lung Cancer Subset

December 21st 2020, 2:00pm

Article

The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.

FDA Approves Tagrisso as Adjuvant Therapy for Non-Small Cell Lung Cancer After Tumor Resection

December 18th 2020, 7:51pm

Article

This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.